# Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

> **NCT06544577** · — · RECRUITING · sponsor: **SciClone Pharmaceuticals** · enrollment: 350 (estimated)

## Conditions studied

- ESR1 Gene Mutation
- Advanced Breast Cancer
- Safety

## Interventions

- **DRUG:** ELacestrant

## Key facts

- **NCT ID:** NCT06544577
- **Lead sponsor:** SciClone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-13
- **Primary completion:** 2025-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06544577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06544577, "Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06544577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*